Aug 10, 2018 9:18 AM - 1 week, 4 days, 2 hours, 19 minutes, 27 seconds ago
FDA Contracts with Company That Sold Fetal Tissue for Tax-Payer Funded Research
By Melanie Israel | August 10, 2018 | 9:18 AM EDT
Earlier this week, CNS News reported that the U.S. Food and Drug Administration recently signed a one-year, $15,900 contract with Advanced Bioscience Resources to acquire human fetal tissue “for implantation into severely immune-compromised mice to create chimeric animals that have a human immune system.”
According to the government’s presolicitation notice, “ABR is the only company in the U.S. capable of supplying” the fetal tissue and “no other company or organization is capable of fulfilling the need.”
In 2015, the Center for Medical Progress released disturbing undercover videos of abortion industry representatives discussing the sale of aborted baby body parts. The ensuing outrage spawned congressional investigation in the House and Senate and resulted in multiple criminal referrals.
ABR is among the entities under referral for criminal investigation for possibly profiting from the sale of fetal tissue from aborted babies. Among its sources for fetal tissue are Planned Parenthood-affiliated clinics.
Fetal tissue used for research purposes may be obtained via elective abortions. Such research is legal, but federal law prohibits buying or selling fetal tissue for valuable consideration. “Valuable consideration” does not include payments “associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.”
According to the Senate Judiciary Committee’s 2016 report, several tissue procurement companies—including ABR—“have paid Planned Parenthood Federation of America to acquire aborted fetuses, and then sold the fetal tissue to their respective customers at substantially higher prices than their documented costs.”
Contrary to the intent of federal law, these companies did not conduct an analysis of their costs when determining fees. Rather, after committee investigation, they resorted to “post hoc accounting rationalizations … in an attempt to justify their fees.”
The House and Senate committees sent criminal referrals for ABR to the Department of Justice, Federal Bureau of Investigation, and the district attorney in Riverside, California. In December 2017,
The New York Timesreported that the Justice Department “appears to be laying the groundwork for an investigation into the transfer of fetal tissue” and requested unredacted documents related to the Senate Judiciary Committee’s investigation.
The FDA’s decision to contract with ABR is troubling, to say the least. In a statement, the FDA said that ABR has “provided assurances with all applicable legal requirements … relating to research involving human fetal tissue” and that the FDA is not involved with how ABR sources the tissue. In other words, the FDA is simply taking ABR at its word, despite the troubling findings of congressional investigations.
According to CNS News, the FDA has contracted with ABR eight times since 2012. Two of those contracts were granted after House and Senate committees issued criminal referrals involving ABR.
More troubling, still, is the continued use of fetal ...
(Click to add to search.)
**The statements and opinions expressed are solely those of the author and do not necessarily reflect those of this website or it's affiliates. The opinions expressed here should not be understood as advocated by or sanctioned by this website or it's affiliates. Information contained on this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness and should not be relied upon. You use this website, information, and content at your own risk. This includes information and content linked to and from this website. Content displayed may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to report the news, advance understanding of the issues, and discover content. We believe this constitutes fair use of any such copyrighted material. Content is removed on a case by case basis. To request that content be removed, contact us using the following form: Contact Us. 4Internet LLC, its members, owners, employees, contractors, customers, users, agents, affiliates, and/or assigns, will not be liabile for any damages.